Table 1. Main characteristics of the studied patients at time of inclusion.
| ALF-5755 | Placebo | p | |
|---|---|---|---|
| N | 28 | 29 | |
| M/W | 9/21 | 14/15 | NS |
| Age (Mean±SD) | 43.5±14.8 | 40.0±15.3 | NS |
| BMI (Mean±SD) | 24.5±5.0 | 23.3±4.4 | NS |
| Etiology (N patients) | NS | ||
| HAV | 4 | 6 | |
| HBV | 9 | 4 | |
| AIH | 4 | 5 | |
| Drug induced | 4 | 4 | |
| Unknown1 | 3 | 5 | |
| Others | 4 | 5 | |
| Concomitant NAC2 (N, %) | 23 (82.1) | 24 (82.7) | NS |
| Hepatic encephalopathy (N, %) | 3 (10.3) | 3 (11.1) | NS |
| Bilirubin | 303 (17–612) | 212 (18–511) | NS |
| ASAT | 2157 (98–27033) | 1440 (123–8643) | NS |
| ALAT | 2296 (190–7215) | 3191 (415–7951) | NS |
| Prothrombin rate (Median, range) | 34 (16–49) | 35 (17–49) | NS |
| INR (Median, range) | 2.2 (1.5–4.5) | 2.2 (1.2–4.4) | NS |
| MELD (Median, range) | 26(14–40) | 25 (14–40) | NS |
1. despite complete investigation;
2. N acetyl cysteine.